Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer
Filho O, Ballman K, Campbell J, Liu M, Ligibel J, Watson M, Chen E, Du L, Stover D, Carey L, Partridge A, Kirshner J, Muss H, Hudis C, Winer E, Norton L, Symmans W. Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer. Journal Of Clinical Oncology 2025, 43: 1229-1239. PMID: 39746162, DOI: 10.1200/jco-24-01875.Peer-Reviewed Original ResearchConceptsDose-dense chemotherapyDisease-free survivalOverall survivalBreast cancerTumor burdenMenopausal statusLong-term disease-free survivalHormone receptor-positive breast cancerHazard ratioNode-positive breast cancerSensitivity to endocrine therapyReceptor-positive breast cancerDose-dense therapyER-negative subsetEstrogen receptor-positiveER+ breast cancerMolecular subtype classificationSustained long-term benefitsER+ cancersDose-denseER statusReceptor-positiveEndocrine therapyConventional chemotherapyChemotherapy schedule
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply